Former Lilly executive joins AMRI
Charles Jensen is appointed as DMPK director
Jensen brings more than 20 years of experience working in drug metabolism and toxicology in the pharmaceutical industry. His strong technical background and project management experience will strengthen AMRI’s capabilities in the DMPK area and further enhance the US firm’s global platform of integrated discovery biology and chemistry services.
Jensen’s experience includes 15 years at Eli Lilly and Co, where he rose to senior study director for Drug Development Services for In Vitro Technologies. Prior to Lilly, he worked for RTI Health Solutions, where he established a full-service in vitro DMPK-toxicology laboratory and developed a robust intestinal permeability/Pgp transport model.
‘Dr Jensen’s DMPK expertise adds additional depth to AMRI’s leading drug discovery team and will help position the company as it expands its involvement with fully integrated discovery biology and chemistry programmes,’ commented Sargent.
You may also like
Manufacturing
Curia enters cooperative agreement with US government to expand sterile fill-finish capability
Curia, formerly AMRI, a leading contract research, development and manufacturing organisation, announces a cooperative agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR), the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the US Army Contracting Command to support the domestic production of injectable medicines
